BioXcel Therapeutics
BTAI
83 hedge funds and large institutions have $287M invested in BioXcel Therapeutics in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 17 closing their positions.
138% more call options, than puts
Call options by funds: $3.21M | Put options by funds: $1.35M
105% more capital invested
Capital invested by funds: $140M → $287M (+$147M)
0.35% more ownership
Funds ownership: 2.65% → 3% (+0.35%)
2% less funds holding
Funds holding: 85 → 83 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.2M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$7.65M |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$4.57M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.78M |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$929K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.96M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$1.05M |
| 3 |
Two Sigma Investments
New York
|
-$668K |
| 4 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$617K |
| 5 |
Goldman Sachs
New York
|
-$606K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Nisa Investment Advisors
St. Louis,
Missouri
| – | +$242 | +1 | New |
|
BTAI Hedge Fund Activity: Q4 2022 in Review
83 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2022, worth a combined $287M — up 105% from $140M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of BTAI and 15 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 23 added.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $13.2M. The largest seller was Morgan Stanley, cutting an estimated $1.96M.
- 83 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2022, down from 85 in Q3 2022.
- Funds reported $287M of BioXcel Therapeutics stock for Q4 2022, up 105% quarter-over-quarter.
- 15 funds opened new BioXcel Therapeutics positions in Q4 2022 and 17 closed out, a net change of -2 holders.
- The largest BioXcel Therapeutics buyer in Q4 2022 was Adage Capital Partners, an estimated $13.2M added.
- The largest BioXcel Therapeutics seller in Q4 2022 was Morgan Stanley, an estimated $1.96M sold.
Based on aggregated 13F filings for Q4 2022.